鼻内递送纳米脂质体SN-38治疗弥漫性中线胶质瘤
本研究在DIPG患者来源异种移植模型中评估鼻内递送纳米脂质体伊立替康(LS-CPT-11)及其活性代谢物SN-38(LS-SN-38)的疗效。LS-SN-38在体外抑制DIPG细胞生长和集落形成并增加凋亡,优于LS-CPT-11;鼻内递送LS-SN-38使脑干肿瘤SN-38浓度达0.66±0.25 ng/ml(血清浓度的5.43%±0.31%),并较LS-对照(p<0.0001)和LS-CPT-11(p=0.003)显著延长动物生存。
要点
- 鼻内递送LS-SN-38可绕过血脑屏障,将药物递送至脑干肿瘤。
- LS-SN-38在体外抑制DIPG细胞生长和集落形成、增加凋亡,优于LS-CPT-11。
- 鼻内递送LS-SN-38较LS-对照(p<0.0001)和LS-CPT-11(p=0.003)显著延长动物生存。
核心结论
- 本研究证明鼻内递送LS-SN-38可绕过血脑屏障,实现对脑干肿瘤高效无创的药物递送,为治疗DIPG提供有前景的治疗方法。
研究设计与样本
- 在DIPG患者来源异种移植模型中评估鼻内递送纳米脂质体伊立替康(LS-CPT-11)及其活性代谢物SN-38(LS-SN-38)的疗效。
- 体外采用细胞活力、集落形成和凋亡实验评估DIPG细胞对LS-CPT-11和LS-SN-38的反应。
- 荷DIPG患者来源异种移植瘤小鼠接受鼻内递送LS-对照(空脂质体)、LS-CPT-11或LS-SN-38治疗4周。
主要发现
- LS-SN-38抑制DIPG细胞生长和集落形成并增加凋亡,优于LS-CPT-11。
- 罗丹明标记的LS-SN-38在治疗后30分钟开始出现细胞内荧光信号,24小时达峰。
- 液相色谱-质谱分析显示脑干肿瘤中SN-38浓度为0.66±0.25 ng/ml(血清浓度的5.43%±0.31%)。
- 鼻内递送LS-SN-38较鼻内递送LS-对照(p<0.0001)和LS-CPT-11(p=0.003)延缓肿瘤生长并显著延长动物生存。
- 鼻内递送LS-SN-38增加脑干肿瘤中TUNEL阳性细胞数并减少Ki-67阳性细胞。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Diffuse midline gliomas, including diffuse intrinsic pontine gliomas (DIPGs), are among the most malignant and devastating childhood brain cancers. Despite aggressive treatment, nearly all children with these tumors succumb to their disease within 2 years of diagnosis. Due to the anatomical location of the tumors within the pons, surgery is not a treatment option, and distribution of most systematically administered drugs is limited by the blood-brain barrier (BBB). New drug delivery systems that bypass the BBB are desperately needed to improve outcomes of DIPG patients. Intranasal delivery (IND) is a practical and noninvasive drug delivery system that bypasses the BBB and delivers the drugs to the brain through the olfactory and trigeminal neural pathways. In this study, the authors evaluated the efficacy of nanoliposomal (LS) irinotecan (CPT-11) and an active metabolite of CPT-11, 7-ethyl-10-hydroxycamptothecin (SN-38), using IND in DIPG patient-derived xenograft models. METHODS: In vitro responses to LS-CPT-11 and LS-SN-38 in DIPG cells were evaluated with cell viability, colony formation, and apoptosis assays. The cellular uptakes of rhodamine-PE (Rhod)-labeled LS-CPT-11 and LS-SN-38 were analyzed with fluorescence microscopy. Mice bearing DIPG patient-derived xenografts were treated with IND of LS-control (empty liposome), LS-CPT-11, or LS-SN-38 by IND for 4 weeks. In vivo responses were measured for tumor growth by serial bioluminescence imaging and animal subject survival. The concentration of SN-38 in the brainstem tumor administered by IND was determined by liquid chromatography-mass spectrometry (LC-MS). Immunohistochemical analyses of the proliferative and apoptotic responses of in vivo tumor cells were performed with Ki-67 and TUNEL staining. RESULTS: LS-SN-38 inhibited DIPG cell growth and colony formation and increased apoptosis, outperforming LS-CPT-11. Rhod-labeled LS-SN-38 showed intracellular fluorescence signals beginning at 30 minutes and peaking at 24 hours following treatment. LC-MS analysis revealed an SN-38 concentration in the brainstem tumor of 0.66 ± 0.25 ng/ml (5.43% ± 0.31% of serum concentration). IND of LS-SN-38 delayed tumor growth and significantly prolonged animal survival compared with IND of LS-control (p < 0.0001) and LS-CPT-11 (p = 0.003). IND of LS-SN-38 increased the number of TUNEL-positive cells and decreased the Ki-67-positive cells in the brainstem tumor. CONCLUSIONS: This study demonstrates that IND of LS-SN-38 bypasses the BBB and enables efficient and noninvasive drug delivery to the brainstem tumor, providing a promising therapeutic approach for treating DIPG.
引用
- Sasaki T, Watanabe J, He X, et al. Intranasal delivery of nanoliposomal SN-38 for treatment of diffuse midline glioma. J Neurosurg. 2022. PMID: 36599085. doi:10.3171/2022.9.JNS22715
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。